Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Apr 29, 2014
Dr Stephen Ryder Consultant Physician in Hepatology and Gastroenterology at the Nottingham Digestive Diseases Centre and Biomedical Research Unit.
In the context of the methodology used and the assumptions made, implications of outcomes in England if current hepatitis C treatment rates are maintained. Dr Ryder explores what factors will aﬀect the burden of disease in the UK by 2030. He looks at how new treatments could lead to better cure rates, fewer side eﬀects, shorter treatment. He discusses what will happen to infection levels, hepatocellular carcinoma, liver related deaths, decompensated cirrhosis if there are no changes, how all of these will increase and how diagnostic and treatment rates need to increase.